This is such a stupid argument. Why even ask where the money is going to come from? Everyone here knows that a pre-revenue company needs to sell shares in order to obtain capital to pay for its business operations. The key here, and everyone knows this, is for positive trial data leading to an increase in PPS. The higher the PPS, the less shares that are needed to be sold, resulting in better value for the shareholders of Oncolix. It's really simple stuff.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.